Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Biologic response modifier (interleukin-2)

Aldesleukin

Proleukin

Dosage form
Tablet
Available strengths
22 million International Units (1.3 mg) per vial
Drug class
Biologic response modifier (interleukin-2)
Common brand
Proleukin

Clinical overview. Aldesleukin (brand name Proleukin) is a recombinant interleukin-2 immunotherapy used to treat adults with metastatic renal cell carcinoma or metastatic malignant melanoma. It is given by intravenous infusion in a hospital setting under close monitoring, since it can cause severe, whole-body side effects including capillary leak syndrome, low blood pressure, and organ dysfunction. Careful patient selection and inpatient supervision are essential throughout treatment.

Indication

Common therapeutic uses

  • Aldesleukin is indicated for the treatment of adults with metastatic renal cell carcinoma.
  • Aldesleukin is indicated for the treatment of adults with metastatic malignant melanoma.
  • Careful patient selection, including cardiac and pulmonary function testing, is required before starting treatment, since therapy is associated with severe, potentially life-threatening side effects.

Pregnancy

Risk assessment and monitoring considerations

  • Aldesleukin has been shown to cause embryo-lethal effects in animal studies at high doses.
  • There are no adequate, well-controlled studies of aldesleukin in pregnant women.
  • Aldesleukin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
  • Men and women of reproductive potential should use effective contraception during treatment, since the effect of aldesleukin on fertility has not been studied.

Breastfeeding

Infant exposure considerations

  • It is not known whether aldesleukin passes into human breast milk.
  • Because of the potential for serious side effects in a nursing infant, a decision should be made to either discontinue breastfeeding or discontinue aldesleukin, taking into account the importance of treatment to the mother.

Geriatrics

Dosing and tolerability considerations

  • No formal clinical trials have compared the safety or efficacy of aldesleukin in older adults versus younger patients.
  • Caution is recommended when prescribing aldesleukin to older patients, since kidney and liver function often decline with age, increasing susceptibility to side effects.

Pediatrics

Use in children and adolescents

  • No data are available on the use of aldesleukin in patients under 18 years of age, and it is not authorized for pediatric use.

Dosage & Administration

Practical dosing and administration

  • The recommended dose is 600,000 international units per kilogram of body weight, given as a 15-minute intravenous infusion every 8 hours.
  • Each treatment cycle consists of up to 14 doses, followed by a 9-day rest period, then another cycle of up to 14 doses, for a maximum of 28 doses per course.
  • Doses are frequently withheld rather than reduced if side effects occur; the decision to stop, hold, or restart therapy is based on an overall assessment of the patient.
  • Patients are re-evaluated for response about 4 weeks after completing a course, and further courses are given only if there has been some tumour shrinkage and retreatment is not contraindicated.
  • Treatment courses should be separated by a rest period of at least 7 weeks from the date of hospital discharge.
  • Reconstituted aldesleukin is diluted in 5% dextrose solution and infused over 15 minutes; a smaller dilution volume is used for patients weighing less than 40 kilograms.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Aldesleukin's side effects are dose-related, so exceeding the recommended dose can cause expected toxicities to appear more quickly.
  • Symptoms that persist after stopping treatment should be monitored and managed with supportive care.
  • Life-threatening toxicity may be eased with intravenous dexamethasone, although this can also reduce aldesleukin's therapeutic effect.

Common side effects

Frequently reported tolerability concerns

  • Chills are very common, occurring in about half of patients.
  • Fever is common.
  • A general feeling of being unwell (malaise) is common.
  • Weakness (asthenia) is common.
  • Diarrhea is very common.
  • Nausea is common.
  • Vomiting is common.
  • Mouth sores (stomatitis) may occur.
  • Decreased appetite is common.
  • Abdominal pain may occur.
  • Abdominal swelling (an enlarged abdomen) may occur.
  • Headache may occur.
  • Chest pain may occur.
  • Rash is common.
  • Itching (pruritus) may occur.
  • Peeling or exfoliative skin reactions may occur.
  • Shortness of breath (dyspnea) is common.
  • Increased cough may occur.
  • Fluid retention and swelling (edema) are common.
  • Weight gain may occur.
  • Confusion may occur.
  • Drowsiness (somnolence) may occur.
  • Low blood pressure (hypotension) is very common and expected with treatment.
  • Fast heart rate (tachycardia) may occur.
  • Reduced urine output (oliguria) is common.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Capillary leak syndrome, marked by fluid and protein leaking out of blood vessels, can cause a severe drop in blood pressure and reduced blood flow to organs; this is expected to some degree with nearly every course of treatment.
  • Serious heart rhythm disturbances (arrhythmias) may occur.
  • Heart attack (myocardial infarction) may occur.
  • Inflammation of the heart muscle (myocarditis) may occur, sometimes causing lasting reduction in heart pumping function.
  • Cardiac tamponade (fluid buildup around the heart) may occur.
  • Respiratory failure severe enough to require intubation and mechanical ventilation may occur.
  • Significant kidney function decline may occur, sometimes requiring dialysis.
  • Liver function impairment may occur, occasionally progressing to signs of hepatic failure.
  • Serious bloodstream infections and sepsis may occur, partly because aldesleukin can impair the body's ability to fight bacteria.
  • Bacterial endocarditis (infection of the heart valves) has been reported, particularly in patients with indwelling catheters.
  • Significant mental status changes, including confusion, agitation, or hallucinations, may occur.
  • Coma may occur in severe cases.
  • Seizures may occur, particularly in patients with a prior seizure disorder.
  • Gastrointestinal bleeding may occur.
  • Bowel ischemia or perforation may occur.
  • Exacerbation of pre-existing autoimmune conditions, such as inflammatory arthritis, scleroderma, or thyroid disease, has been reported.
  • Fatal tumor lysis syndrome has been reported when aldesleukin was combined with certain chemotherapy agents such as cisplatin, vinblastine, and dacarbazine.
  • Seek urgent medical attention for chest pain, severe shortness of breath, sudden confusion, signs of infection such as fever, or a significant drop in urine output.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with any history of cardiac, pulmonary, renal, hepatic, or central nervous system impairment; treatment is contraindicated if function is not normal at baseline.
  • Use with caution in patients with pre-existing autoimmune or inflammatory disorders, since aldesleukin may trigger flares.
  • Use with caution in patients with diabetes or blood sugar abnormalities, since aldesleukin can disrupt glucose metabolism.
  • Use with caution in patients with indwelling central venous catheters, given the increased risk of serious bacterial infection.
  • Use with caution in patients undergoing surgery or anesthesia, and in transplant recipients, due to the risk of allograft rejection from enhanced immune activity.
  • Patients should not drive or operate machinery during treatment, since aldesleukin can cause dizziness, drowsiness, or loss of consciousness.
  • Close inpatient monitoring, including daily vital signs, cardiac and pulmonary assessment, and laboratory testing, is required throughout treatment.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with a known history of hypersensitivity to interleukin-2 or any component of the formulation.
  • Contraindicated in patients with an abnormal thallium stress test or abnormal pulmonary function tests.
  • Contraindicated in patients who have received an organ transplant.
  • Retreatment is contraindicated in patients who experienced sustained ventricular tachycardia, uncontrolled cardiac arrhythmias, chest pain with ECG changes, or cardiac tamponade during a prior course.
  • Retreatment is contraindicated in patients who required intubation for more than 72 hours, dialysis for renal failure lasting more than 72 hours, or coma or toxic psychosis lasting more than 48 hours during a prior course.
  • Retreatment is contraindicated in patients with repetitive or difficult-to-control seizures, bowel ischemia or perforation, or gastrointestinal bleeding requiring surgery during a prior course.

Drug interactions

Clinically relevant combinations

  • Combining aldesleukin with other antineoplastic agents may increase toxicity to the heart, bone marrow, liver, kidneys, and central nervous system.
  • Glucocorticoids can reduce the anti-tumour effectiveness of aldesleukin and should generally be avoided except to manage severe or life-threatening reactions.
  • Iodinated contrast media used for imaging may provoke more frequent or severe reactions in patients who have recently received aldesleukin.
  • Concurrent use of nephrotoxic drugs may worsen kidney function during treatment.
  • Concurrent use of hepatotoxic drugs may worsen liver function during treatment.
  • Centrally acting drugs, such as psychotropic medications, may have additive effects on the central nervous system.
  • Antihypertensive medications may add to the blood-pressure-lowering effects of aldesleukin-associated capillary leak syndrome.
  • Concomitant use with cisplatin, vinblastine, and dacarbazine is not recommended, given reports of fatal tumor lysis syndrome.

Food interactions

Meal-related administration

  • No specific food interactions have been established for aldesleukin.

Time of administration

Practical scheduling

  • Aldesleukin is administered as a scheduled intravenous infusion in hospital, typically every 8 hours during active treatment cycles; there is no relationship to meal timing since it is not taken by mouth.

Storage

Product handling

  • Store unopened vials under refrigeration between 2°C and 8°C.
  • The reconstituted and diluted solution should also be kept refrigerated and brought to room temperature before infusion, and used within 48 hours of reconstitution.

Patient take-away

Key counselling points for a quick closing summary

  • Aldesleukin (Proleukin) is a powerful immune-stimulating therapy used for certain advanced cancers and is given only in a hospital setting under close specialist supervision.
  • Side effects, including fever, chills, and low blood pressure, are expected with nearly every course and are actively managed by the treatment team.
  • Report any chest pain, severe shortness of breath, confusion, or reduced urination to your care team immediately, as these can signal serious complications.
  • Effective contraception is required during treatment, since the effects of aldesleukin on a developing baby are not fully known.

References

Source material and product information

  1. Health Canada Product Monograph — Aldesleukin

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.